QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Fortrea Holdings Inc. (FTRE)

Healthcare

No action
Fundamental
2
Sentiment
4
Technical
3

Do Nothing: fundamentalScore is 2 (below required floor of 3); strategy requires fundamentalScore >= 3 before any bullish entry.

Analysis as of 2026-08-06· about 2 trading days ago

Company overview

Fortrea Holdings Inc. is a global contract research organization providing development services for biopharmaceutical products and medical devices. It operates through Clinical Services and Enabling Services segments, offering clinical trial management and technology solutions. Founded in 2023, the company is headquartered in Durham, North Carolina.

Fundamental

weak
Fundamental2
Elevated-risk turnaround

Fortrea faces weak GAAP profitability and leverage risks, offset by positive free cash flow and low EV/Sales.

Fortrea shows positive free cash flow and a low EV/Sales, but GAAP profitability remains weak (impairment-driven losses) and leverage/interest burden is still a key risk. SEC disclosures highlight reliance on winning new awards and customer concentration. FundamentalScore: 2 (elevated-risk turnaround).

Sentiment

good
Sentiment4
Constructive sentiment

Recent media coverage is positive, but retail engagement is low and no immediate catalysts are present.

The key near-term driver is Fortrea’s Q2’26 results and raised FY26 revenue guidance (announced 2026-07-29), and the last ~14 days of third‑party coverage skews positive (earnings-beat recaps plus upgrade-style notes). Baseline (30–90d) media coverage is too sparse to compute a firm sentiment delta, but the Red-Flag Screen is clean (only plaintiff-law-firm solicitation noise; no regulator-confirmed investigation).

Technical

fair
Technical3
Mixed post-earnings pullback

The broader trend is constructive, but the stock is digesting a post-earnings spike and trades below short-term averages.

Broader trend remains constructive because FTRE is above the SMA50 (17.35) and SMA200 (13.82) with MACD still above zero, but price is below the SMA20/EMA9/EMA21/VWAP stack, RSI14 is only 49.33, Williams %R is -79.85, and MACD (0.48) sits below its 0.67 signal; this is a mixed post-earnings pullback rather than a confirmed short-term continuation.

You’re looking at 2026-08-06 — about 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.